Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

NCT02553317 is registered in ClinicalTrials.gov with Ablynx, a Sanofi company as lead sponsor.

NCT NCT02553317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02553317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Lead sponsor
Ablynx, a Sanofi company
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2015
Completion date
August 31, 2017
Enrollment
145 (actual)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

acquired thrombotic thrombocytopenic purpura